Expert opinion on managing chronic HCV in patients with neuropsychiatric manifestations.

Abstract:

:Neurological manifestations of HCV infection appear to be under-recognized in clinical practice despite the majority of HCV-infected patients experiencing symptoms such as fatigue, depression and cognitive dysfunction. There is also growing evidence for a link between HCV infection and an increased risk of Parkinson's disease. The mechanism underpinning the association between HCV and these neuropsychiatric syndromes still requires further investigation. Here we review the pre-clinical and clinical evidence for a link between HCV and effects on the central nervous system leading to neuropsychiatric syndromes. Lastly, we describe how improvements in neuropsychiatric manifestations of HCV following treatment have been observed, which is subsequently reflected in an overall improvement in health-related quality of life.

journal_name

Antivir Ther

journal_title

Antiviral therapy

authors

Forton D,Weissenborn K,Bondin M,Cacoub P

doi

10.3851/IMP3245

subject

Has Abstract

pub_date

2018-01-01 00:00:00

pages

47-55

issue

Suppl 2

eissn

1359-6535

issn

2040-2058

journal_volume

23

pub_type

杂志文章,评审
  • The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells.

    abstract:OBJECTIVES:Clinical disorders occurring in HIV-infected patients on antiretroviral therapy (ART) have been linked to mitochondrial dysfunction, for example, lactic acidosis and lipodystrophy. Mitochondrial membrane potential (delta psi m) is the most direct measure of the state of energization of the mitochondria. We a...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Sternfeld T,Schmid M,Tischleder A,Mudra S,Schlamp A,Kost BP,Gruber R,Youle M,Bogner JR,Goebel FD

    更新日期:2007-01-01 00:00:00

  • In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosis.

    abstract:BACKGROUND:In vitro studies have reported controversial effects of protease inhibitors (PIs) on mitochondrially driven apoptosis. Additionally, since PIs in the clinical setting are almost always given in combination with nucleoside analogues, which may have negative effects on mitochondrial DNA (mtDNA), the impact of ...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Miró O,Villarroya J,Garrabou G,López S,Rodríguez de la Concepción M,Pedrol E,Martínez E,Giralt M,Gatell JM,Cardellach F,Casademont J,Villarroya F

    更新日期:2005-01-01 00:00:00

  • Non-steroidal anti-inflammatory drugs increase the antiretroviral activity of nucleoside reverse transcriptase inhibitors in HIV type-1-infected T-lymphocytes: role of multidrug resistance protein 4.

    abstract:BACKGROUND:The multidrug resistance proteins (MRPs) form a subfamily within the ATP binding cassette transporters that confer resistance to a variety of structurally unrelated compounds. MRP4 has been reported to transport antiretroviral drugs out of cells in an active process. Although the main therapeutic effects of ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1468

    authors: Clemente MI,Alvarez S,Serramía MJ,Turriziani O,Genebat M,Leal M,Fresno M,Muñoz-Fernández MA

    更新日期:2009-01-01 00:00:00

  • The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.

    abstract::Boceprevir and telaprevir are peptidomimetic serine protease inhibitors that have been recently approved for the treatment of HCV chronic infection. The addition of these drugs to the prior standard of care, pegylated interferon and ribavirin, improves sustained virological response rates for treatment-naive and treat...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP2424

    authors: Marks KM,Jacobson IM

    更新日期:2012-01-01 00:00:00

  • Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conception.

    abstract:BACKGROUND:Little is known about pregnancy patterns and levels of HIV RNA in HIV-infected women conceiving on highly active antiretroviral therapy (HAART) with non-suppressed viral load (VL), nor about their therapeutic management. METHODS:Linear mixed models were fitted to study changes in VL and potential associated...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:10.3851/IMP1489

    authors: European Collaborative Study.

    更新日期:2010-01-01 00:00:00

  • Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.

    abstract:BACKGROUND:Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved for HIV-1 infected, antiretroviral treatment-naive adults based on data from two Phase III trials. In the screening population, the prevalence of 49 NNRTI resistance-associated mutations (RAMs) and the impact of allowed...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,随机对照试验

    doi:10.3851/IMP2358

    authors: Vingerhoets J,Rimsky L,Van Eygen V,Nijs S,Vanveggel S,Boven K,Picchio G

    更新日期:2013-01-01 00:00:00

  • Low density lipoprotein apolipoprotein B metabolism in treatment-naive HIV patients and patients on antiretroviral therapy.

    abstract:BACKGROUND:Dyslipidaemia and lipodystrophy have been described in treated HIV patients and in a small percentage of untreated HIV patients. Lipodystrophy in these patients has been shown to be associated with a lower expression of low density lipoprotein (LDL) receptors. METHODS:We have investigated the effect of anti...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Umpleby AM,Das S,Stolinski M,Shojaee-Moradie F,Jackson NC,Jefferson W,Crabtree N,Nightingale P,Shahmanesh M

    更新日期:2005-01-01 00:00:00

  • Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.

    abstract:BACKGROUND:The aim of this study was to assess the long-term efficacy and safety of first-line treatment with once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs). METHODS:A total of 272 antiretroviral-naive patients with a CD4+ T-cell count of 200-350 cells/mm3 were treated wit...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:

    authors: Ananworanich J,Gayet-Ageron A,Ruxrungtham K,Chetchotisakd P,Prasithsirikul W,Kiertiburanakul S,Munsakul W,Raksakulkarn P,Tansuphasawadikul S,LeBraz M,Jupimai T,Ubolyam S,Schutz M,Hirschel B,Staccato Thailand Study Group.

    更新日期:2008-01-01 00:00:00

  • Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study.

    abstract:BACKGROUND:In China, the optimal management of individuals living with chronic HBV infection remains an unmet need. The EVOLVE was a 5-year prospective, longitudinal, observational study that compared the clinical outcomes in treatment-naïve CHB patients receiving entecavir (ETV) or lamivudine (LAM)-based therapies. M...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3372

    authors: Jia J,Shang J,Tang H,Jiang J,Ning Q,Dou X,Zhang S,Zhang M,Han T,Tan D,Zhou X,Chen G,Sheng J,Su Z,Chen H,Dai E,Ye Y,Guo Y,Shen Y,Yuan J,Wei Z,Zhu S,EVOLVE Study Group.

    更新日期:2020-10-22 00:00:00

  • Altered heterochromatin organization after perinatal exposure to zidovudine.

    abstract:BACKGROUND:Zidovudine (3'-azido-3'-deoxythymidine, AZT), administered to pregnant women alone or in combination with other antiretroviral drugs, greatly reduces the mother-to-child transmission of HIV-1. The potential genotoxicity of these molecules is underestimated and wide-ranging evaluation of its biological and cl...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Senda S,Blanche S,Costagliola D,Cibert C,Nigon F,Firtion G,Floch C,Parat S,Viegas-Péquignot E

    更新日期:2007-01-01 00:00:00

  • Effect of long-term lamivudine in chronic hepatitis B virus-infected children.

    abstract:OBJECTIVE:To evaluate, retrospectively, biochemical, serological and histological responses in chronic hepatitis B (CHB)-infected children who received combination therapy and continued with prolonged treatment with lamivudine (3TC). PATIENTS AND METHODS:CHB infection was defined as the presence of hepatitis B surface...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Ozgenç F,Arikan C,Sertoz RY,Nart D,Aydogdu S,Yagci RV

    更新日期:2004-10-01 00:00:00

  • The enrichment of HBV immune-escape mutations during nucleoside/nucleotide analogue therapy.

    abstract:BACKGROUND:Drug-resistant HBV mutants frequently arise during nucleoside/nucleotide analogue (NA) therapy, while the resistance mutations on polymerase also have consequent changes in the S protein. The enrichment of immune-escape mutations was negatively correlated with hepatitis B surface antigen (HBsAg) clearance un...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3156

    authors: Shan M,Shen Z,Sun H,Zheng J,Zhang M

    更新日期:2017-01-01 00:00:00

  • Experience with nevirapine in previously treated HIV-1-infected individuals.

    abstract:OBJECTIVE:To assess the tolerability, virological, immunological and clinical effects of nevirapine in the setting of a compassionate use programme in pretreated HIV-infected individuals. DESIGN:Retrospective observational cohort-study in 13 HIV-outpatient clinics in The Netherlands. METHODS: MAIN OUTCOME MEASURES:p...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Wit FW,Dutch HIV-treating physicians.

    更新日期:2000-12-01 00:00:00

  • Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents.

    abstract:BACKGROUND:Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor drug, could be a favourable drug for maintenance therapy in HIV-infected adolescents because it has few long-term side effects. However, data among adolescents switching from efavirenz (EFV) to RPV are limited. This study investigated the ph...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究

    doi:10.3851/IMP3198

    authors: Jantarabenjakul W,Anugulruengkitt S,Kasipong N,Thammajaruk N,Sophonphan J,Bunupuradah T,Cressey TR,Colbers A,Burger DM,Phongsamart W,Puthanakit T,Pancharoen C,HIVNAT 220 study.

    更新日期:2018-01-01 00:00:00

  • Pleconaril-resistant chronic parechovirus-associated enteropathy in agammaglobulinaemia.

    abstract::A 14 year old common variable immunodeficiency patient developed severe protein-losing enteropathy. A chronic enteral infection with human parechovirus type 1 and norovirus was diagnosed. Treatment strategies aimed at virus eradication and providing supportive care were ineffective. The antipicornavirus agent pleconar...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP1792

    authors: van de Ven AA,Douma JW,Rademaker C,van Loon AM,Wensing AM,Boelens JJ,Sanders EA,van Montfrans JM

    更新日期:2011-01-01 00:00:00

  • Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures.

    abstract:BACKGROUND:The potential use of variola virus as a biological weapon has renewed efforts in the development of antiviral agents against orthopoxviruses. ST-246 [4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-di oxo-4,6-ethenocycloprop [f]isoindol-2(1 H)-yl)-benzamide] is an anti-orthopoxvirus compound active ag...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Duraffour S,Snoeck R,de Vos R,van Den Oord JJ,Crance JM,Garin D,Hruby DE,Jordan R,De Clercq E,Andrei G

    更新日期:2007-01-01 00:00:00

  • Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients.

    abstract::Solid organ transplantation in HIV-infected individuals requires concomitant use of immunosuppressants and antiretrovirals that may cause significant drug interactions. Here we report on a peculiar pharmacokinetic interaction between tacrolimus and protease inhibitors (PIs) which occurred in four HIV-infected liver tr...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Pea F,Tavio M,Pavan F,Londero A,Bresadola V,Adani GL,Furlanut M,Viale P

    更新日期:2008-01-01 00:00:00

  • Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART.

    abstract:BACKGROUND:Proton magnetic resonance spectroscopy (1H-MRS) and neuropsychological tests may be useful for monitoring the effectiveness of highly active antiretroviral therapy (HAART) in HIV-associated brain injury. We aimed to evaluate whether brain abnormalities will improve 3 months after HAART. METHOD:Thirty-three ...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Chang L,Ernst T,Witt MD,Ames N,Walot I,Jovicich J,DeSilva M,Trivedi N,Speck O,Miller EN

    更新日期:2003-02-01 00:00:00

  • Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group.

    abstract::Intravenous ribavirin was provided non-selectively for investigational open-label use among persons with suspected hantavirus pulmonary syndrome (HPS) in the United States between 4 June 1993 and 1 September 1994. Therapy was initiated prior to laboratory confirmation of hantavirus infection because most deaths from H...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Chapman LE,Mertz GJ,Peters CJ,Jolson HM,Khan AS,Ksiazek TG,Koster FT,Baum KF,Rollin PE,Pavia AT,Holman RC,Christenson JC,Rubin PJ,Behrman RE,Bell LJ,Simpson GL,Sadek RF

    更新日期:1999-01-01 00:00:00

  • A phase I/IIa study with succinylated human serum albumin (Suc-HSA), a candidate HIV-1 fusion inhibitor.

    abstract:BACKGROUND:Succinylated human serum albumin (Suc-HAS) is a negatively charged neo-glycoprotein that binds to the positively charged V3-loop of HIV-1 gp120, acting as HIV-1-fusion inhibitor in vitro (IC50: 0.5-5.0 microg/ml). Suc-HSA was safe in rats and monkeys, and showed antiretroviral effect in a human-to-mouse mode...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,随机对照试验

    doi:

    authors: Vermeulen JN,Meijer DK,Over J,Lange J,Proost JH,Bakker HI,Beljaars L,Wit FW,Prins JM

    更新日期:2007-01-01 00:00:00

  • The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies.

    abstract:BACKGROUND:Antibodies to liver-kidney microsome type 1 (anti-LKM-1), which are a marker of autoimmune hepatitis, are found in a minority of patients with chronic hepatitis C virus (HCV) infection. Whether interferon/ribavirin therapy is safe and effective in these patients is unclear. AIM:To describe the prevalence, c...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:

    authors: Monti V,Aghemo A,Rumi MG,Donato MF,Del Ninno E,Colombo M

    更新日期:2005-01-01 00:00:00

  • Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine.

    abstract::The aim of this study (the RESCUE trial) was to verify the effect of a shift from a lamivudine-containing to a didanosine-containing regimen on viral replication in HIV-1-infected subjects who had experienced prior treatment failure. Sixteen patients (didanosine-experienced in 14/16 cases) were consecutively enrolled:...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Rusconi S,La Seta Catamancio S,Citterio P,Bulgheroni E,Kurtagic S,Galazzi M,Croce F,Moroni M,Galli M

    更新日期:2001-03-01 00:00:00

  • HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B.

    abstract::Although chronic HBV infection is the leading cause of chronic liver disease and death worldwide, there are substantial differences in its clinical courses regarding prevalence, mode of transmission, characteristics of each phase, responses to antiviral therapy, and development of cirrhosis and hepatocellular carcinom...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,评审

    doi:10.3851/IMP1982

    authors: Kim BK,Revill PA,Ahn SH

    更新日期:2011-01-01 00:00:00

  • Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?

    abstract:BACKGROUND:Increasing efavirenz (EFV) dose from 600 mg to 800 mg daily has been suggested with concomitant rifampicin (RFN), as induction of cytochrome P450 isoenzymes may reduce EFV plasma concentrations. METHODS:Individuals from the CIPRA-South Africa cohort taking EFV-based antiretroviral therapy with concomitant t...

    journal_title:Antiviral therapy

    pub_type: 临床试验,杂志文章

    doi:10.3851/IMP1780

    authors: Orrell C,Cohen K,Conradie F,Zeinecker J,Ive P,Sanne I,Wood R

    更新日期:2011-01-01 00:00:00

  • A systematic review of a single-class maintenance strategy with nucleoside/nucleotide reverse transcriptase inhibitors in HIV/AIDS.

    abstract:BACKGROUND:Single-drug class regimens with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are generally not recommended as initial therapy because they are inferior compared with therapy with two NRTIs plus efavirenz. However, triple-NRTI combinations can be useful in specific circumstances such as in t...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,meta分析,评审

    doi:10.3851/IMP2726

    authors: Sprenger HG,Bierman WF,van der Werf TS,Gisolf EH,Richter C

    更新日期:2014-01-01 00:00:00

  • Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19.

    abstract::Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 is highly inf...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:10.3851/IMP3362

    authors: Xie X,Jiang Y,Zeng Y,Liu H

    更新日期:2020-06-04 00:00:00

  • Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.

    abstract:BACKGROUND:The tuberculosis (TB) mortality rate of registered TB patients in Malawi is 23%, and 59% of the deaths occur in the first 2 months of treatment. HIV-related complications appear to be an important cause. Starting antiretroviral therapy early during tuberculosis treatment may improve outcome but problems ofte...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: van Oosterhout JJ,Kumwenda JJ,Beadsworth M,Mateyu G,Longwe T,Burger DM,Zijlstra EE

    更新日期:2007-01-01 00:00:00

  • Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.

    abstract:BACKGROUND:Little is known about the efficacy, safety and tolerability of pegylated interferon plus ribavirin treatment in patients with chronic hepatitis Cvirus (HCV) infection and histologically proven fully established cirrhosis. We aimed here to evaluate the safety of this regimen in such patients and to identify b...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:

    authors: Roffi L,Colloredo G,Pioltelli P,Bellati G,Pozzpi M,Parravicini P,Bellia V,Del Poggio P,Fornaciari G,Ceriani R,Ramella G,Corradi C,Rossini A,Bruno S,Gruppo Epatologico Lombardo.

    更新日期:2008-01-01 00:00:00

  • Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA.

    abstract::P-glycoprotein (P-gp) limits bioavailability and accumulation of HIV protease inhibitors (PIs). PIs are ligands for the pregnane-X-receptor (PXR), which regulates P-gp expression. This occurs when ligands activate the receptor, initiating binding to response elements in the MDR1 promoter. PXR also activates cytochrome...

    journal_title:Antiviral therapy

    pub_type: 杂志文章

    doi:

    authors: Owen A,Chandler B,Back DJ,Khoo SH

    更新日期:2004-10-01 00:00:00

  • Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118).

    abstract:BACKGROUND:Amdoxovir (2,6-diaminopurine dioxolane; DAPD) is a nucleoside reverse transcriptase inhibitor (NRTI) of human immunodeficiency virus-1 (HIV-1) with activity against wild-type and NRTI-resistant viruses. METHODS:ACTG A5118 assessed the antiretroviral activity and safety of DAPD (300 mg orally, twice daily) v...

    journal_title:Antiviral therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:

    authors: Gripshover BM,Ribaudo H,Santana J,Gerber JG,Campbell TB,Hogg E,Jarocki B,Hammer SM,Kuritzkes DR,A5118 Team.

    更新日期:2006-01-01 00:00:00